| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424681000 | Magnesium chloride | 13 |
| 20080241277 | Herbal formulation for the treatment of bone fractures and osseous defects - An herbal formulation including | 10-02-2008 |
| 20090117205 | Quinolone-containing medicinal composition - The present invention relates to a pharmaceutical solution comprising the following components (A) and (B): | 05-07-2009 |
| 20090169648 | COMPOSITIONS TO REDUCE BLOOD GLUCOSE LEVELS AND TREAT DIABETES - The invention discloses compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). Composition 1 (Comp1) reinforces efficacy of Mg salt to reduce glucose level by the combination of Mg salt with anti-inflammatory agents konjac-glucomannan (KGM), vitamin C and alpha-lipoic acid (α-LA). Composition 2 (Comp2) provides safety for chromium picolinate (CrPic) by the combination of CrPic with anti-inflammatory agents KGM, vitamin C and α-LA that inhibits oxygen radicals. Compositions may optionally include cinnamon extract (CE) or another insulinogenic nutraceutical agent, American ginseng (AG), | 07-02-2009 |
| 20100136141 | Hemostatic agent - A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material. | 06-03-2010 |
| 20110151024 | Compositions and Methods for Preventing Migraines - The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases. | 06-23-2011 |
| 20110189309 | TOPICAL MEDICAMENT - The present invention relates, in general, to topical medicinal formulations that provide pain relief and enhance recovery from injury. In particular, the invention relates to a topical medicinal formulation comprising 0.35 to 35% of a soluble salt of a biologically acceptable alkali metal or alkaline earth metal such as sodium, potassium, lithium, magnesium and calcium and their use in methods of treating pain or enhancing healing. | 08-04-2011 |
| 20110244058 | Compositions and methods for treatment of pulmonary diseases and conditions - The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors or ketamine at specific pH. The compositions preferably comprise brimonidine and/or dexmedetomidine and/or ketamine. | 10-06-2011 |
| 20110262563 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 10-27-2011 |
| 20110318431 | Pharmaceutical Compositions and Methods of Treating Neurological Insults - A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain injury. | 12-29-2011 |
| 20140193524 | METHOD AND COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS - The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that sea water has more magnesium in it than in naturally occurring seawater. The treatment of acne and the like can be improved with the product of the present invention. | 07-10-2014 |
| 20140342021 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR NEUROLOGICAL DISORDERS - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 11-20-2014 |
| 20150010650 | COMPOSITIONS COMPRISING BIOMEMBRANE SEALING AGENT FOR TREATMENT OF PAIN OR INFLAMMATION, AND METHODS OF USE - The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant. | 01-08-2015 |
| 20150064285 | SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF - The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea. | 03-05-2015 |
